Press coverage about Lexicon Pharmaceuticals (NASDAQ:LXRX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Lexicon Pharmaceuticals earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.7494790323434 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of brokerages have commented on LXRX. BidaskClub lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. Wedbush reiterated an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Finally, Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $28.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 2.04% during mid-day trading on Thursday, hitting $12.03. The stock had a trading volume of 423,835 shares. Lexicon Pharmaceuticals has a 12 month low of $11.62 and a 12 month high of $19.50. The firm’s 50-day moving average is $13.53 and its 200 day moving average is $15.00. The company’s market cap is $1.27 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $18.34 million. During the same period in the previous year, the business earned ($0.37) earnings per share. The firm’s revenue was down 40.3% on a year-over-year basis. Equities analysts anticipate that Lexicon Pharmaceuticals will post ($1.46) EPS for the current fiscal year.

In other Lexicon Pharmaceuticals news, insider Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, September 15th. The stock was acquired at an average cost of $12.54 per share, for a total transaction of $376,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.77% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals (LXRX) Receiving Somewhat Positive News Coverage, Analysis Shows” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/lexicon-pharmaceuticals-lxrx-receiving-somewhat-positive-news-coverage-analysis-shows/1611108.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.